Vantrexa · SCLC · United States · Thoracic medical oncologist · captured by James Whitfield on 08 May 2026 · reviewed by Dr. Marcus Lindqvist on 13 May 2026
Verbatim as captured; never edited
Thoracic medical oncologist at Johns Hopkins raised duration of response during a scientific exchange. They indicated this influences their current prescribing approach.
Human-approved by Dr. Marcus Lindqvist on 13 May 2026
Duration of response: recurring question reported by thoracic medical oncologist (US).
helixor-private-llm-2026.05 · generated 08 May 2026, 10:00 UTC
AI summary
Duration of response raised by thoracic medical oncologist; relevant for Medical Communications.
Source spans used by the model
Thoracic medical oncologist at Johns Hopkins raised duration of response during a scientific exchange. They indicated this influences their current prescribing approach.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Product understanding | Product understanding |
| Function | Medical Communications | Medical Communications |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 3 | 20% | 12.0 |
| Strategic alignment | 4 | 20% | 16.0 |
| Scientific importance | 3 | 15% | 9.0 |
| Urgency | 1 | 15% | 3.0 |
| Novelty | 1 | 10% | 2.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 4 | 5% | 4.0 |
| Breadth of occurrence | 2 | 5% | 2.0 |
| Total | Medium 56 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
08 May 2026 · Dr. Daniel Weber, Johns Hopkins · MSL James Whitfield
Insight
Reviewed 13 May 2026 by Dr. Marcus Lindqvist
Action
Publication project · David Chen · In progress
Decision
Outcome
Closure
Shared with Clinical Development; no further action required.